{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:16:01Z","timestamp":1793103361886,"version":"4.5.0"},"reference-count":17,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuromuscular Diseases"],"published-print":{"date-parts":[[2024,3,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Spinal muscular atrophy (SMA) is a progressive neuromuscular disease caused by mutations in Survival motor neuron 1 ( SMN1) gene, leading to reduction in survival motor neuron protein (SMN), key for motor neuron survival and function in the brainstem and spinal cord. Risdiplam is an orally administered SMN2-splicing modifier which increases production of functional SMN protein. Risdiplam was offered in the UK under early access to medicines scheme (EAMS) to SMA type 1 and 2 patients aged 2 months and older, not suitable for authorised treatments from September 2020 to December 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To describe the largest paediatric European real-world set of data on patients\u2019 characteristics and short-term safety for risdiplam in Great Britain through EAMS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We collated data from SMA REACH UK a national clinical and research network for all patients enrolled onto EAMS and assessed all submitted adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of the 92 patients; 78% were Type 2 SMA, mean age 10.9 years, range 0\u201317 years. 56 were treatment na\u00efve, 33 previously treated; of these 25 had received nusinersen, 3 previous treatment unknown. Sixty adverse events (AEs) were reported occurring in 34 patients. The commonest were respiratory tract infections and gastrointestinal disturbance. Four life-threatening events were reported with 2 deaths and permanent cessation of risdiplam in 3 patients. Overall, 38\/60 AEs were considered unrelated to risdiplam, 10\/60 related to risdiplam and for 12\/60 causality not specified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This study found a safety profile similar to clinical trials with no new safety concerns identified. With the restricted eligibility of onasemnogene abeparvovec and complications of nusinersen administration, EAMS allowed access or continued treatment to na\u00efve patients or patients no longer suitable for approved medications. Collection of longitudinal data for this complex population is needed, to provide greater insights into risdiplam\u2019s role in addressing patients\u2019 needs into the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3233\/jnd-230162","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T10:46:53Z","timestamp":1704451613000},"page":"361-368","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Risdiplam in Spinal Muscular Atrophy: Safety Profile and Use Through The Early Access to Medicine Scheme for the Paediatric Cohort in Great Britain"],"prefix":"10.1177","volume":"11","author":[{"given":"Nikki","family":"Cornell","sequence":"first","affiliation":[{"name":"The Dubowitz Neuromuscular Centre, Developmental Neuroscience Research and Teaching Department, UCL Great Ormond Street Institute of Child Health, NIHR Great Ormond Street Hospital Biomedical Research Centre & Great Ormond Street Hospital NHS Foundation Trust, UCL Great Ormond Street Institute of Child Health, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Childs","sequence":"additional","affiliation":[{"name":"Leeds Royal Infirmary, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Wraige","sequence":"additional","affiliation":[{"name":"Evelina London Childrens Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinki","family":"Munot","sequence":"additional","affiliation":[{"name":"The Dubowitz Neuromuscular Centre, Developmental Neuroscience Research and Teaching Department, UCL Great Ormond Street Institute of Child Health, NIHR Great Ormond Street Hospital Biomedical Research Centre & Great Ormond Street Hospital NHS Foundation Trust, UCL Great Ormond Street Institute of Child Health, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Ambegaonkar","sequence":"additional","affiliation":[{"name":"Addenbrookes Hospital, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Chow","sequence":"additional","affiliation":[{"name":"Queen\u2019s Medical Centre Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imelda","family":"Hughes","sequence":"additional","affiliation":[{"name":"Royal Manchester Children\u2019s Hospital, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie","family":"Illingworth","sequence":"additional","affiliation":[{"name":"University Hospital Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anirban","family":"Majumdar","sequence":"additional","affiliation":[{"name":"Bristol Royal Hospital for Children, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Marini-Bettolo","sequence":"additional","affiliation":[{"name":"John Walton Muscular Research Centre, Newcastle University and Newcastle upon Tyne Hospitals NHS Foundation trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Parasuraman","sequence":"additional","affiliation":[{"name":"University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Spinty","sequence":"additional","affiliation":[{"name":"Alder Hey Children\u2019s Hospital, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"Willis","sequence":"additional","affiliation":[{"name":"The Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariacristina","family":"Scoto","sequence":"additional","affiliation":[{"name":"The Dubowitz Neuromuscular Centre, Developmental Neuroscience Research and Teaching Department, UCL Great Ormond Street Institute of Child Health, NIHR Great Ormond Street Hospital Biomedical Research Centre & Great Ormond Street Hospital NHS Foundation Trust, UCL Great Ormond Street Institute of Child Health, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Baranello","sequence":"additional","affiliation":[{"name":"The Dubowitz Neuromuscular Centre, Developmental Neuroscience Research and Teaching Department, UCL Great Ormond Street Institute of Child Health, NIHR Great Ormond Street Hospital Biomedical Research Centre & Great Ormond Street Hospital NHS Foundation Trust, UCL Great Ormond Street Institute of Child Health, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On Behalf of the Paediatric UK Risdiplam EAMS Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"key":"ref001","doi-asserted-by":"publisher","DOI":"10.1086\/338627"},{"key":"ref002","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2009965"},{"key":"ref003","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02420-8"},{"key":"ref004","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51560"},{"key":"ref005","unstructured":"European Medicines Agency. Spinraza Summary of Product Characteristics[online]. Last updated 22\/02\/2021. [Accessed 13 Dec 2022]. Available from:<https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/spinraza>"},{"key":"ref006","unstructured":"European Medicines Agency. Zolgensma Summary of Product Characteristics [online]. Last updated 19\/04\/2021.[Accessed 13 Dec 2022] Available from: <httpswww.ema.europa.eu\/en\/medicines\/human\/EPAR\/zolgensma>"},{"key":"ref007","unstructured":"European Medicines Agency. Evrysdi Summary of Product Characteristics[online]. Published: 04\/05\/2021. [Accessed 7 July 2023] Available via: <https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/evrysdi>"},{"key":"ref008","unstructured":"Medicines and Healthcare products Regulatory agency. Early Access to Medicines Scheme \u2013Treatment protocol \u2013Risdiplam. Information on the pharmacovigilance system and requirements for reporting safety data [online]. [Accessed 23 Mar 23] Available via: <https\/\/www.gov.uk\/government\/publications\/risdiplam-in-the-treatmentof-type-1-and-type-2-spinal-muscular-atrophy-sma-inpatients-2-months-of-age-and-older>"},{"key":"ref009","unstructured":"Medicines and Healthcare products Regulatory agency. Yellow Card | Making medicines and medical devices safer[online]. [Accessed 11 May 23] Available via:<https:\/\/yellowcard.mhra.gov.uk>"},{"key":"ref010","unstructured":"National Institute for Health and Care Excellence. Managed Access Agreement \u2013nusinersen 5q SMA [online]. Issued July 2019. [Accessed 11 Apr 2023] Available via: <http:\/\/www.nice.org.uk\/guidance\/ta588\/resources\/managed-access-agreement-july-2019-pdf-6842812573>"},{"key":"ref011","doi-asserted-by":"publisher","DOI":"10.1007\/s00132-021-04131-7"},{"key":"ref012","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00367-7"},{"key":"ref013","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00339-8"},{"issue":"7","key":"ref014","doi-asserted-by":"crossref","first-page":"7S29","DOI":"10.1016\/S0929-693X(20)30274-8","volume":"27","author":"Fauroux B","year":"2023","journal-title":"Arch Pediatr[online]"},{"key":"ref015","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.11.005"},{"key":"ref016","unstructured":"ServaisL, BaranelloG, BertiniE, ChiribogaC, DarrasB, DayJ et al. on behalf of the Firefish, Sunfish and Jewelfish Study Groups. Pooled safety data from the risdiplam clinical trial development program; presented at Muscular dystrophy association virtual clinical and scientific conference, 15-18 March 2021, MDA Virtual Conference Platform. [Accessed 24 Feb 23]. Available from:<https:\/\/mdaconference.org\/node\/1160>"},{"key":"ref017","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27804"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JND-230162","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/JND-230162","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JND-230162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:52:37Z","timestamp":1777506757000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JND-230162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3,5]]}},"alternative-id":["10.3233\/JND-230162"],"URL":"https:\/\/doi.org\/10.3233\/jnd-230162","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,4]]}}}